Sana Biotechnology (SANA) Free Cash Flow (2020 - 2026)
Sana Biotechnology recorded quarterly Free Cash Flow of -$37.7 million in Q1 2026, down 12.39% quarter-over-quarter from -$33.5 million in Q4 2025, and up 22.8% year-over-year from -$30.7 million in Q1 2025.
Sana Biotechnology's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$37.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 22.8% year-over-year to -$37.7 million; the TTM figure through Mar 2026 stood at -$133.6 million (up 29.84% YoY), while the FY2025 annual figure was -$144.8 million, up 35.13% from the prior year.
- Free Cash Flow came in at -$37.7 million for Q1 2026 at Sana Biotechnology, down from -$33.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$29.5 million in Q3 2025 to a low of -$81.5 million in Q1 2024.
- A 5-year average of -$57.6 million and a median of -$51.5 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 52.88% in 2022 and surged 40.11% in 2025, its largest moves.
- Sana Biotechnology's Free Cash Flow stood at -$80.7 million in 2022, then soared by 36.16% to -$51.5 million in 2023, then grew by 8.92% to -$46.9 million in 2024, then climbed by 28.55% to -$33.5 million in 2025, then slipped by 12.39% to -$37.7 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$37.7 million, -$33.5 million, and -$29.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - | -37.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.67 Mn |
| Mar 31, 2026 | -37.67 Mn |
| Dec 31, 2025 | -33.51 Mn |
| Dec 31, 2025 | -33.51 Mn |
| Sep 30, 2025 | -29.49 Mn |
| Sep 30, 2025 | -29.49 Mn |
| Jun 30, 2025 | -32.97 Mn |
| Jun 30, 2025 | -32.97 Mn |
| Mar 31, 2025 | -48.79 Mn |
| Mar 31, 2025 | -48.79 Mn |
| Dec 31, 2024 | -46.90 Mn |
| Dec 31, 2024 | -46.90 Mn |
| Sep 30, 2024 | -48.70 Mn |
| Sep 30, 2024 | -48.70 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Mar 31, 2024 | -81.48 Mn |
| Mar 31, 2024 | -81.48 Mn |
| Dec 31, 2023 | -51.50 Mn |
| Dec 31, 2023 | -51.50 Mn |
| Sep 30, 2023 | -71.53 Mn |
| Sep 30, 2023 | -71.53 Mn |
| Jun 30, 2023 | -59.79 Mn |
| Jun 30, 2023 | -59.79 Mn |
| Mar 31, 2023 | -80.24 Mn |
| Mar 31, 2023 | -80.24 Mn |
| Dec 31, 2022 | -80.67 Mn |
| Dec 31, 2022 | -80.67 Mn |
| Sep 30, 2022 | -69.15 Mn |
| Sep 30, 2022 | -69.15 Mn |
| Jun 30, 2022 | -79.98 Mn |
| Jun 30, 2022 | -79.98 Mn |
| Mar 31, 2022 | -81.13 Mn |
| Mar 31, 2022 | -81.13 Mn |
| Dec 31, 2021 | -88.45 Mn |
| Dec 31, 2021 | -88.45 Mn |
| Sep 30, 2021 | -58.55 Mn |
| Sep 30, 2021 | -58.55 Mn |
| Jun 30, 2021 | -54.00 Mn |
| Jun 30, 2021 | -54.00 Mn |
| Mar 31, 2021 | -53.07 Mn |
| Mar 31, 2021 | -53.07 Mn |
| Dec 31, 2020 | -46.83 Mn |
| Dec 31, 2020 | -46.83 Mn |
| Sep 30, 2020 | -43.83 Mn |
| Sep 30, 2020 | -43.83 Mn |
| Jun 30, 2020 | -36.06 Mn |
| Jun 30, 2020 | -36.06 Mn |
| Mar 31, 2020 | -35.15 Mn |
| Mar 31, 2020 | -35.15 Mn |